ReviewFrontiers in oncology2018

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer.

Tarah J Ballinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.